$FTH

Faeth Therapeutics, Inc.

Faeth Therapeutics is a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling, with a focus on improving outcomes for cancer patients. Its lead program is PIKTOR, an investigational oral combination of serabelisib and sapanisertib designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. PIKTOR is being evaluated for advanced endometrial and breast cancers. The company’s other programs include NEAAR and IEM. Faeth develops therapeutics through clinical trials and has an ongoing Phase 2 study of PIKTOR in second-line advanced endometrial cancer. It also plans a Phase 1b study in advanced HR+/HER2- breast cancer. Faeth Therapeutics is based in Austin, Texas.

AlphAI earnings readThird Quarter 2026 · NOV 3Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational UpdatesVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

2
1
0

No SEC Form 4 filings for $FTH in the last 30 days.

See all $FTH insider activity →
Med

Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) stock rose 10.1% in pre-market trading after presenting Phase II endometrial cancer data at the Jefferies Global Healthcare Conference, showing a 33% overall response rate. The company also announced a clinical partnership with Roche. H.C. Wainwright reiterated its Buy rating and $60 price target, citing a 55% stock decline since November 9 as disconnected from clinical progress.

Faeth Therapeutics stock gets $60 target on Roche collaboration

Faeth Therapeutics (FTH) received a $60 price target from H.C. Wainwright after announcing a clinical trial collaboration with Roche to evaluate PIKTOR in combination with giredestrant for advanced breast cancer. The stock has fallen 55% since November 9, trading at $9.28. Analysts cite undervaluation and positive Phase 2 trial results for PIKTOR in endometrial cancer, with a 33% response rate.

FTH sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning FTH (Faeth Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.

Recent FTH coverage spans financial news, market movers and technology.

What's driving FTH

  • Clinical response and progression-free survival metrics plus Roche collaboration are likely to drive renewed risk-on biotech demand and momentum buying.

    investing.com · Nov 18, 2026

  • Collaboration expands the PIKTOR endocrine backbone strategy and adds a near-term catalyst via ongoing Phase 1b/2 PIK-101 and prior Phase 2 PIK-201 readout.

    investing.com · Nov 17, 2026

  • Positive trial data may limit further downside but the recent steep sell‑off suggests continued pressure.

    rttnews.com · Nov 16, 2026

  • Positive Phase 2 data and analyst upgrades suggest upside potential.

    investing.com · Nov 11, 2026

  • Citigroup kept its Buy rating on Faeth Therapeutics and increased its price target to $60 from $55. This implies a 373.2% upside from the Nov 9 close of $12.68. Recent analyst price targets for the company range from $55 to $69.

    tradingview.com · Nov 10, 2026

AlphAI scores every news story that mentions FTH with an AI model for sentiment and relevance, and aggregates insider trades from Faeth Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $FTH

Score

Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) stock rose 10.1% in pre-market trading after presenting Phase II endometrial cancer data at the Jefferies Global Healthcare Conference, showing a 33% overall response rate. The company also announced a clinical partnership with Roche. H.C. Wainwright reiterated its Buy rating and $60 price target, citing a 55% stock decline since November 9 as disconnected from clinical progress.

Faeth Therapeutics stock gets $60 target on Roche collaboration

Faeth Therapeutics (FTH) received a $60 price target from H.C. Wainwright after announcing a clinical trial collaboration with Roche to evaluate PIKTOR in combination with giredestrant for advanced breast cancer. The stock has fallen 55% since November 9, trading at $9.28. Analysts cite undervaluation and positive Phase 2 trial results for PIKTOR in endometrial cancer, with a 33% response rate.

$FTHHighAI 8/10

Why This Recently Rebranded Biotech Just Crashed 45%

Faeth Therapeutics (FTH) shares fell over 40% after reporting that only 33% of patients responded to its experimental endometrial cancer treatment, PIK-201, combined with paclitaxel. The analysis included 36 evaluable patients, with six excluded. Investors reacted negatively to the effectiveness data.

$FTHMedAI 8/10Clinical / regulatory· topline data

FAETH THERAPEUTICS PIKTOR Phase 2 Endometrial Cancer Topline Results NOVEMBER 9, 2026

Faeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Other Events. FAETH THERAPEUTICS PIKTOR Phase 2 Endometrial Cancer Topline Results NOVEMBER 9, 2026 Exhibit 99.1 This Presentation contains forward-looking statements of Faeth Therapeutics, Inc. (the “Company”) within the meaning of the federal securities laws. Words such as “may,” “will,” “sh

$FTHHighAI 8/10

Faeth Therapeutics stock maintained at Buy by TD Cowen on trial data

TD Cowen maintained a Buy rating on Faeth Therapeutics (FTH) after its PIKTOR study showed a 33% objective response rate and 7.4 months median progression-free survival, exceeding chemotherapy benchmarks. FTH stock surged 14.7% last week, trading at $22.05. Analysts note potential in endometrial cancer treatment, with mixed views on valuation. Recent ratings include Overweight (Cantor Fitzgerald), Market Outperform (Citizens, $51 target), and Outperform (William Blair, $66 target).

$FTHHighAI 9/10Clinical / regulatory· topline data

Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced…

Faeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer • Confirmed Objective Response Rate (ORR) of 33% in efficacy-evaluable patients (12 of 36),

Related tickers